Related Experiment Video
Updated: Oct 5, 2026

08:28
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
HER-2 and choice of adjuvant chemotherapy in breast cancer
1Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA.
Seminars in Oncology
|August 11, 2001
Abstract:
The amplification or overexpression of HER-2 is a recognized prognostic marker that is associated with poor survival for patients with node-positive breast cancer. Several studies have demonstrated that HER-2 may serve to direct the selection of optimal adjuvant chemotherapy. This article provides a critical review of the studies that offer evidence for the role of HER-2 as a predictor of response to chemotherapy.